Introduction
More than 40 peptides are known to exist in mammalian neurons, where they serve chemical-messenger functions [ 1, 21 . In most instances, however, we lack the pharmacological tools, in the form of non-peptide-drug molecules, which act as agonists or antagonists at neuropeptide receptors. The example of morphine shows, however, that a single, non-peptide structure can provide all the information needed to develop large numbers of synthetic compounds with agonist or antagonist actions [3] . More 
Discovery and development of synthetic CCK antagonists
The Merck compounds all derive from a naturalproduct lead, asperlicin (Fig. l) , from the fungus Aspergillus alliaceus [7] . This was discovered in a screening programme using the binding of radioiodinated CCK-8S to CCK receptors in rat pancreatic membranes as the primary assay. Asperlicin proved to have submicromolar potency in displacing IZ5I-CCK-XS, and acted as a competitive antagonist of the contractions elicited by CCK-XS in guinea pig ileum and gall bladder with similar submicromolar potency [7] .
Using asperlicin as a lead for medicinal chemistry, it proved possible to simplify this complex, heterocylic molecule and to synthesize more potent derivatives. Devazepide (also known as 1,-364718 and MK-329) was one such synthetic derivative (Fig. l) , approximately 100-fold more potent than the natural product [XI. Like asperlicin, devazepide has selectivity for the CCK-A receptors found in gastrointestinal-tract tissues, and has conAbbreviation used: CCK. cholecystokinin. siderably lower affinity for the CCK-B receptors in brain, or gastrin receptors in stomach (Table 1) .
Further medicinal chemistry research, however, led to the discovery of compounds with the reverse selectivity, e.g. 1,-36.5260 ( 
Functional studies in vivo
Devazepide inhibited CCK-stimulated gall-bladder contraction, pancreatic exocrine secretion and colonic contraction [ 1 11. In pilot studies in human volunteers orally administered devazepide (10 mg) effectively prevented the CCK-induced increase in plasma pancreatic-polypeptide (PP) levels. Ilevazepide also blocked post-prandial increases in PP, while having no effect on plasma insulin-, glucagonor glucose-responses to a mixed meal [ 121. Thus, devazepide offers a valuable research tool for studying the physiological role of CCK in regulating pancreatic endocrine function in man.
The CCK-Wgastrin antagonist, I,-365 260, has a number of effects in viva As predicted, the compound acts as an inhibitor of gastrin-induced gastric-acid secretion [lo], although there is little effect on basal levels of acid secretion. In terms of central nervous system effects, attention has focused on three topics: (i) Analgesia. There is evidence that CCK acts as a functional antagonist of opiates [ 131, and CCK antagonists have been found to have the opposite effect, i.e. to enhance opiate-induced analgesia. In addition, the CCK antagonists were able to inhibit the development of tolerance to the analgesic effects of morphine on chronic treatment animals exogenously administered CCK-4 also appeares 'anxiogenic' in reducing exploratory behaviour of animals placed in a novel or fearprovoking environment [20, 211 . I,-365 260 is able to block the 'anxiogenic' effects of CCK-4 or pentagastrin. 1,-365260 is also active in animal models thought to be predictive of anxiolytic drugs: these include the 'elevated-plus-maze', 'punished-drinking' and 'light-dark-box' paradigms [21, 221. 1,-365260 is not the only CCK-H antagonist in development. Recently, a chemically unrelated compound PD 134308 was described, derived by rational design from the C-terminal sequence of CCK. This compound also demonstrates high affinity and selectivity for CCK-H sites in brain. Studies in vivo have shown that, like 1,-365260, it also enhances opiate analgesia, blocks the anxiogenic effects of pentagasterin, and displays anxiolytic activity in animal behavioural models [21, 23, 
241.
In addition, a series of quinazolines with nanomolar affinity and high selectivity for CCK-H sites has been described, derived by rational design from asperlicin [25] .
Clinical applications
It is too early to predict whether the novel synthetic CCK antagonists will have important therapeutic applications. CCK-A-selective compounds such as devazepide might have utility in treating pancreatic disorders and in the control of excessive gut motility. Devazepide itself, however, caused an abnormal incidence of gall stones in long-term animal-toxicity studies, suggesting that chronic use of such compounds may not be possible.
With CCK-&'gastrin-selective compounds there are a number of potential applications; to control gastric-acid secretion, to enhance appetite and food intake in conditions of anorexia, to enhance the effectiveness of opiate analgesics and to inhibit the development of tolerance to such drugs, and in the 
